Herold Advisors Inc. increased its position in shares of West Pharmaceutical Services, Inc. (NYSE:WST – Get Rating) by 14.5% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 807 shares of the medical instruments supplier’s stock after purchasing an additional 102 shares during the period. Herold Advisors Inc.’s holdings in West Pharmaceutical Services were worth $244,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in WST. American International Group Inc. raised its holdings in West Pharmaceutical Services by 0.3% during the fourth quarter. American International Group Inc. now owns 23,223 shares of the medical instruments supplier’s stock worth $10,892,000 after purchasing an additional 59 shares in the last quarter. Fiduciary Trust Co. grew its position in West Pharmaceutical Services by 8.0% in the fourth quarter. Fiduciary Trust Co. now owns 713 shares of the medical instruments supplier’s stock worth $334,000 after buying an additional 53 shares during the last quarter. Gotham Asset Management LLC grew its position in West Pharmaceutical Services by 93.3% in the fourth quarter. Gotham Asset Management LLC now owns 1,260 shares of the medical instruments supplier’s stock worth $591,000 after buying an additional 608 shares during the last quarter. Siemens Fonds Invest GmbH grew its position in West Pharmaceutical Services by 28.8% in the fourth quarter. Siemens Fonds Invest GmbH now owns 1,006 shares of the medical instruments supplier’s stock worth $474,000 after buying an additional 225 shares during the last quarter. Finally, Nissay Asset Management Corp Japan ADV grew its position in West Pharmaceutical Services by 1.8% in the fourth quarter. Nissay Asset Management Corp Japan ADV now owns 13,973 shares of the medical instruments supplier’s stock worth $6,553,000 after buying an additional 250 shares during the last quarter. Institutional investors own 91.98% of the company’s stock.
Insiders Place Their Bets
In other West Pharmaceutical Services news, insider Silji Abraham sold 5,374 shares of West Pharmaceutical Services stock in a transaction that occurred on Monday, August 1st. The shares were sold at an average price of $343.93, for a total transaction of $1,848,279.82. Following the transaction, the insider now directly owns 3,201 shares in the company, valued at approximately $1,100,919.93. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 0.60% of the stock is currently owned by company insiders.
West Pharmaceutical Services Price Performance
West Pharmaceutical Services (NYSE:WST – Get Rating) last posted its quarterly earnings results on Thursday, July 28th. The medical instruments supplier reported $2.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.19 by $0.28. The firm had revenue of $771.30 million for the quarter, compared to analyst estimates of $754.25 million. West Pharmaceutical Services had a net margin of 23.41% and a return on equity of 29.08%. The firm’s quarterly revenue was up 6.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.46 earnings per share. Research analysts forecast that West Pharmaceutical Services, Inc. will post 9.09 earnings per share for the current year.
West Pharmaceutical Services Profile
West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.
- Get a free copy of the StockNews.com research report on West Pharmaceutical Services (WST)
- Why Does Tesla Stock Remain Resilient?
- Are Layoffs At A Small-Cap Tech A Bellwether For Housing Stocks?
- 2 Semiconductor Stocks To Watch For Reversals
- Is Costco’s Post-Earnings Price Weakness A Good Time To Buy?
- Will Crowdstrike Get A Boost From Increased EPS Guidance?
Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.